Oxford Nanopore and Day Zero Diagnostics Partner to Develop a New Class of Bloodstream Infection Diagnostics
Oxford Nanopore, the company delivering a new generation of nanopore-based molecular sensing technology, and Day Zero Diagnostics (DZD)
This article is featured on another website.
Myrtelle Announces Presentation at the 5 th Annual Gene Therapy for Neurological Disorders Summit: Optimizing Gene Therapies Targeting the CNS to Deliver Safe & Efficacious Treatment Options For Neurological Disorder Patients
Wakefield, Mass., November 7, 2023 – Myrtelle Inc. (“Myrtelle” or the “Company”), a clinical-stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases…
Myrtelle Announces Presentation at the 5 th Annual Gene Therapy for Neurological Disorders Summit: Optimizing Gene Therapies Targeting the CNS to Deliver Safe & Efficacious Treatment Options For Neurological Disorder Patients
Wakefield, Mass., November 7, 2023 – Myrtelle Inc. (“Myrtelle” or the “Company”), a clinical-stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases…
Day Zero Diagnostics to Present AI-Based Antimicrobial Susceptibility Testing Predictive Models at IDWeek
Day Zero Diagnostics selected to deliver two presentations at the 2023 ID Week conference and present AI-based antimicrobial susceptibility
Day Zero Diagnostics to Present AI-Based Antimicrobial Susceptibility Testing Predictive Models at IDWeek
Day Zero Diagnostics selected to deliver two presentations at the 2023 ID Week conference and present AI-based antimicrobial susceptibility